NANO Share Price Performance
Recent NANO News & Updates
No updates
Nanobiotix S.A. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.42
- Gross Margin
- 100.00%
- Net Profit Margin
- 947.59%
- Debt/Equity Ratio
- -71.0%
Nanobiotix S.A. Competitors
About NANO
- Founded
- 2003
- Employees
- 108
- CEO
- WebsiteView website
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
French Market Performance
- 7 Days: -3.9%
- 3 Months: -3.5%
- 1 Year: 2.8%
- Year to Date: 0.7%
Over the last 7 days, the market has dropped 3.9%, driven by a pullback of 7.9% in the Consumer Discretionary sector. Overall the market has been flat in the last year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading